![]() |
市场调查报告书
商品编码
1764857
2031年北美动脉血气分析试剂盒市场预测 - 区域分析 - 按註射器类型、种类、用途、应用、针头规格、注射器容量和最终用户North America Arterial Blood Gas Kits Market Forecast to 2031 - Regional Analysis - by Syringe Type, Type, Usage, Application, Needle Gauge, Syringe Volume, and End User |
2023 年北美动脉血气试剂盒市值为 3,01,799.63 千美元,预计到 2031 年将达到 5,34,661.28 千美元;预计 2023 年至 2031 年的复合年增长率为 7.4%。
呼吸系统疾病发生率上升推动北美动脉血气分析试剂盒市场
气喘、慢性阻塞性肺病 (COPD) 和肺炎等呼吸系统疾病给世界各国的公共医疗系统带来了沉重的负担。感染、吸烟和遗传因素都可能导致严重的呼吸系统併发症。慢性阻塞性肺病 (COPD) 是全球第四大死因,2021 年导致 350 万人死亡,约占全球死亡总数的 5%。 70 岁以下族群中约 90% 的 COPD 相关死亡发生在中低收入国家 (LMIC)。 2021 年,美国肺臟协会将 COPD 列为美国第三大死因,当年有超过 1,640 万人被诊断出患有 COPD。根据美国气喘和过敏基金会的数据,2022 年美国约有 2,600 万人患有气喘。联合国国际儿童紧急基金会 (UNICEF) 表示,每年每 10 万名儿童中约有 1,400 名(即每 71 名儿童中就有 1 名)被诊断出患有肺炎。呼吸系统疾病患者通常会出现呼吸困难和缺氧。动脉血气 (ABG) 测试用于测量溶解在血液中的氧气和二氧化碳气体。该测试是急性和慢性呼吸系统疾病患者护理的基础。因此,急性和慢性呼吸系统疾病发病率的激增推动了对动脉血气检测试剂盒的需求。
北美动脉血气试剂盒市场概览
根据美国心臟衰竭协会 (HFSA) 于 2023 年启动的 HF Stats (SM) 计划,预计每 4 人中就有 1 人 (约 25%) 会在一生中患上 HF,高于先前估计的每 5 人中 1 人 (约 20%)。根据 HFSA 资料库 HF Stats,约有 670 万 20 岁以上的美国人患有 HF,预计到 2030 年患病人数将上升到 850 万人。 HF 的终身风险已增加至 24%,即预计每 4 人中就有 1 人会在一生中罹患 HF。根据美国气喘和过敏基金会的数据,2022 年美国约有 2,600 万人患有气喘,气喘是世界上最常见的呼吸系统疾病之一。呼吸道感染会导致更严重的疾病,导致住院或死亡。由于与年龄相关的问题,例如虚弱和免疫衰老,老年人的死亡率高于年轻人。气喘是老年人最常见的呼吸系统疾病之一。根据 2020 年人口普查,2020 年美国老年人口达到 5,580 万人(占总人口的 16.8%),预计 2012 年至 2050 年期间老年人口将大幅上升。这些人需要更了解呼吸系统疾病对其健康的影响,因为患有呼吸系统疾病的患者通常会因缺氧而出现呼吸问题。动脉血气分析以分氧压 (PaO2) 和分二氧化碳压 (PaCO2) 的形式评估患者动脉血中的溶解氧和二氧化碳含量。 PaCO2 提供有关通气状态(急性或慢性呼吸衰竭)的信息,而 PaO2 则提供有关氧合状态的资讯。需要动脉血气分析的慢性疾病(包括呼吸衰竭、急性呼吸窘迫症候群 (ARDS)、气喘、糖尿病酮症酸中毒、肾小管性酸中毒、心臟衰竭 (HF) 和先天性代谢性疾病)的盛行率日益上升,是美国在动脉血气试剂盒市场占据最大份额的主要原因。此外,美国在技术进步方面的稳固地位也显着促进了各种动脉血气试剂盒及相关技术的普及。
北美动脉血气试剂盒市场收入及预测(2031 年)(千美元)
北美动脉血气试剂盒市场细分
北美动脉血气分析试剂盒市场分为注射器类型、类型、用途、应用、针头规格、注射器容量、最终用户和国家。
根据注射器类型,北美动脉血气分析试剂盒市场分为鲁尔滑动注射器和鲁尔锁注射器。鲁尔锁注射器在2023年占据了较大的市场份额。
就类型而言,北美动脉血气分析仪市场分为带通气孔型和非带通气孔型。 2023年,带通气孔型占据了较大的市场份额。
根据用途,北美动脉血气分析试剂盒市场分为预设柱塞式和手动抽吸式。预设柱塞式在2023年占据了较大的市场份额。
根据应用,北美动脉血气分析试剂盒市场分为体外诊断和电解质分析。 2023年,体外诊断领域占据了更大的市场。此外,体外诊断领域也细分为血气pH值、血氧含量和其他。
就针头规格而言,北美动脉血气分析试剂盒市场细分为小于23G、23G至25G和大于25G。 2023年,23G至25G针头占据了最大的市场。
根据注射器容量,北美动脉血气分析试剂盒市场细分为1毫升、3毫升和其他容量。 2023年,3毫升注射器占据了最大的市场份额。
按最终用户划分,北美动脉血气分析试剂盒市场分为医院和诊所、诊断实验室和其他。 2023年,医院和诊所占据了最大的市场。
根据国家/地区,北美动脉血气试剂盒市场细分为美国、加拿大和墨西哥。 2023年,美国占据了北美动脉血气试剂盒市场的主导地位。
Radiometer Medical ApS、Vyaire Medical Inc、Opti Medical Systems、Siemens Healthineers AG、AdvaCare Pharma USA LLC、Becton Dickinson and Co、ICU Medical Inc、SunMed Group Holdings LLC (AirLife)、Trudell Healthcare Solutions Inc、SARSTEDT AG & Co KG 和乐普医疗试剂盒市场领先的动脉血气试剂盒市场领先的动脉血气试剂盒市场领先的动脉血气试剂盒市场领先的动脉血气试剂盒市场领先的动脉血气试剂盒市场领先的动脉血气。
The North America arterial blood gas kits market was valued at US$ 3,01,799.63 thousand in 2023 and is expected to reach US$ 5,34,661.28 thousand by 2031; it is estimated to register a CAGR of 7.4% from 2023 to 2031.
Increasing Incidence of Respiratory Diseases Fuels North America Arterial Blood Gas Kits Market
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia lead to a huge burden on public healthcare systems in various countries across the world. Infections, smoking, and genetic factors can cause serious respiratory complications. Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally, resulting in 3.5 million deaths in 2021, which represents about 5% of all deaths worldwide. Approximately 90% of COPD-related deaths among individuals under 70 years of age occur in low- and middle-income countries (LMIC). In 2021, the American Lung Association ranked COPD third among the leading causes of death in the US, and over 16.4 million people are diagnosed with the condition that year. As per the Asthma and Allergy Foundation of America, ~26 million people in the US had asthma in 2022. The United Nations International Children's Emergency Fund (UNICEF) stated that nearly 1,400 per 100,000 children, i.e., 1 case per 71 children, are diagnosed with pneumonia every year. Breathing issues and oxygen shortages are common in patients suffering from respiratory disorders. Arterial blood gas (ABG) tests are performed to measure oxygen and carbon dioxide gases dissolved in blood. The test serves as a basis of care delivered to patients suffering from acute and chronic respiratory disease. Thus, the surging incidence of acute and chronic respiratory diseases propels the demand for arterial blood gas test kits.
North America Arterial Blood Gas Kits Market Overview
According to the HF Stats (SM) initiative launched by the Heart Failure Society of America (HFSA) in 2023, 1 in 4 individuals (~25%) are expected to experience HF in their lifetime, a rise from the previous estimate of 1 in 5 individuals (~20%). As per HF Stats, an HFSA database, ~6.7 million Americans over 20 years of age suffer HF, and the prevalence is expected to rise to 8.5 million Americans by 2030. The lifetime risk of HF has increased to 24%, i.e., ~1 in every 4 individuals is projected to suffer from HF in their lifetime. According to the Asthma and Allergy Foundation of America, ~26 million people in the US had asthma in 2022, one of the world's most common respiratory diseases. Respiratory infections cause more severe disease, leading to hospitalizations or death. Mortality is more common in older persons than in younger ones due to age-related issues such as frailty and immunosenescence. Asthma is one of the most common respiratory diseases among senior citizens. According to the 2020 Census, the geriatric population reached 55.8 million (16.8%) of the total US population in 2020, and it is projected to rise significantly during 2012-2050. These individuals need a greater understanding of the impact of respiratory diseases on their health, as patients suffering from respiratory disorders usually experience breathing issues due to oxygen shortage. Arterial blood gas analysis evaluates dissolved oxygen and carbon dioxide content, in the form of partial oxygen pressures (PaO2) and partial carbon dioxide pressures (PaCO2), in the arterial blood of patients. PaCO2 gives information on ventilation status (acute or chronic respiratory failure), while PaO2 provides insights into oxygenation status. The growing prevalence of chronic diseases necessitating arterial blood gas analysis, including respiratory failure, acute respiratory distress syndrome (ARDS), asthma, diabetic ketoacidosis, renal tubular acidosis, heart failure (HF), and congenital metabolic diseases, is the major factor contributing to the largest share of the US in the arterial blood gas kits market. Moreover, the country's well-established position in terms of technological advancements contributes notably to the availability of various arterial blood gas kits and associated technologies.
North America Arterial Blood Gas Kits Market Revenue and Forecast to 2031 (US$ Thousand)
North America Arterial Blood Gas Kits Market Segmentation
The North America arterial blood gas kits market is categorized into syringe type, type, usage, application, needle gauge, syringe volume, end user, and country.
Based on syringe type, the North America arterial blood gas kits market is bifurcated into luer slip syringe and luer lock syringe. The luer lock syringe segment held a larger market share in 2023.
In terms of type, the North America arterial blood gas kits market is bifurcated into vented and non-vented. The vented segment held a larger market share in 2023.
By usage, the North America arterial blood gas kits market is bifurcated into pre-set plunger mode and manual aspiration. The pre-set plunger mode segment held a larger market share in 2023.
Based on application, the North America arterial blood gas kits market is bifurcated into in vitro diagnostics and electrolyte analysis. The in vitro diagnostics segment held a larger market share in 2023. Furthermore, the in vitro diagnostics segment is sub segmented into pH blood gas, oxygen content, and others.
In terms of needle gauge, the North America arterial blood gas kits market is segmented into less than 23G, 23G to 25G, and greater than 25G. The 23G to 25G segment held the largest market share in 2023.
Based on syringe volume, the North America arterial blood gas kits market is segmented into 1ml, 3ml, and others. The 3ml segment held the largest market share in 2023.
By end user, the North America arterial blood gas kits market is categorized into hospitals & clinics, diagnostic laboratories, and others. The hospitals & clinics held the largest market share in 2023.
Based on country, the North America arterial blood gas kits market is segmented into the US, Canada, and Mexico. The US dominated the North America arterial blood gas kits market share in 2023.
Radiometer Medical ApS, Vyaire Medical Inc, Opti Medical Systems, Siemens Healthineers AG, AdvaCare Pharma USA LLC, Becton Dickinson and Co, ICU Medical Inc, SunMed Group Holdings LLC (AirLife), Trudell Healthcare Solutions Inc, SARSTEDT AG & Co KG, and Lepu Medical Technology Beijing Co Ltd. are among the leading companies operating in the North America arterial blood gas kits market.